We sought to generate alloreactive leukemia-reactive cytotoxic T lymphocytes from haploidentical parents by culture of peripheral blood mononuclear cells in vitro with irradiated leukemic blasts and IL-2 from children with ALL. After 21 days in culture the mean cytotoxicity of haploidentical lymphocytes against ALL blasts was 38% (n = 11). Cultured parental CTL were not leukemia specific but alloreactive as evidenced by equivalent cytotoxicity against stimulating ALL blasts and ConA-stimulated blasts from the other parent. The cultures yielded primarily CD8 + T cells (59%). Irradiation of CTL limited proliferation by 96% but had no shortterm effects on leukemia reactive cytotoxicity, suggesting a means to limit GVHD potential in vivo. One patient was treated for relapse of ALL post-haploidentical transplant with CTL generated from the original donor. A total of nine infusions were given: the first three were irradiated, while the last six were not due to disease progression. The patient experienced clearance of peripheral blasts, and despite concomitant infusion of IL-2 with the last three CTL infusions, did not experience immediate GVHD reactions. We conclude that ALL blasts are sufficiently immunostimulatory to generate in vitro CTL with provision of exogenous IL-2, and that these CTL could exert an anti-leukemia effect in vivo. Improvements in supportive care, prevention or treatment of transplant-related complications, and molecular methods for histocompatibility testing have decreased the procedurerelated morbidity of allogeneic SCT for acute leukemia, but leukemic relapse often remains a major cause of death. Depletion of T lymphocytes from the donor graft decreases the risk of acute graft-versus-host disease (GVHD) after allogeneic SCT but does not consistently improve diseasefree survival because the reduced mortality from GVHD may be offset by increased risks of graft failure, infection and other complications. T lymphocytes are also the primary mediators of the graft-versus-leukemia (GVL) effect through recognition of minor and major histocompatibility antigens 4,5 or possibly leukemia-specific antigens. 6 The importance of this cellular immunologic antitumor activity is shown by the high relapse rates observed in patients who have received T cell-depleted SCT from haploidentical related donors for acute lymphoblastic leukemia (ALL). 7, 8 Although the use of haploidentical related SCT increases the number of potentially curative allogeneic transplants for acute leukemia, there is a need to develop a strategy that restores the GVL effect that is otherwise diminished as a result of the lymphocyte depletion used in processing the haploidentical donor stem cell product.
Improvements in supportive care, prevention or treatment of transplant-related complications, and molecular methods for histocompatibility testing have decreased the procedurerelated morbidity of allogeneic SCT for acute leukemia, but leukemic relapse often remains a major cause of death. Depletion of T lymphocytes from the donor graft decreases the risk of acute graft-versus-host disease (GVHD) after allogeneic SCT but does not consistently improve diseasefree survival because the reduced mortality from GVHD may be offset by increased risks of graft failure, infection and other complications. T lymphocytes are also the primary mediators of the graft-versus-leukemia (GVL) effect through recognition of minor and major histocompatibility antigens 4, 5 or possibly leukemia-specific antigens. 6 The importance of this cellular immunologic antitumor activity is shown by the high relapse rates observed in patients who have received T cell-depleted SCT from haploidentical related donors for acute lymphoblastic leukemia (ALL). 7, 8 Although the use of haploidentical related SCT increases the number of potentially curative allogeneic transplants for acute leukemia, there is a need to develop a strategy that restores the GVL effect that is otherwise diminished as a result of the lymphocyte depletion used in processing the haploidentical donor stem cell product. 9, 10 To further elucidate and differentiate GVL and GVHD reactions, we evaluated in vitro generation and expansion of parental haploidentical cytotoxic T lymphocyte (CTL) effectors cells derived from peripheral blood lymphocytes (PBL) and directed against ALL blasts obtained from their children. We particularly focused on practical aspects of the generation of these cells for potential clinical application as therapeutic donor leukocyte infusions (DLI). 6, 11, 12 We found that CTL could readily be generated and expanded from parental PBL by using irradiated ALL blasts as allostimulators, despite their lack of expression of CD80 or CD86, by addition of exogenous IL-2 to the co-cultures. We further investigated the effects of graded doses of gamma-irradiation on the proliferation of these alloreactive CTL, as a means to limit or prevent GVHD while retaining a GVL effect after in vivo infusion.
Based upon the preclinical data, a study was opened to examine the in vivo effects of cultured allogeneic CTL for treatment of relapsed leukemia post allogeneic SCT. We describe a patient with ALL which relapsed after haplo-identical SCT treated with allogeneic CTL from the original parental donor. The patient received a total of nine separate infusions, only the first three of which were irradiated secondary to disease progression. Despite receiving relatively large doses (almost 2 ϫ 10 7 CTL/kg with the final infusion) of CTL and concomitant IL-2 with the final three infusions, the patient tolerated the CTL very well, with no immediate signs or symptoms of GVHD. There was documented clearance of both peripheral and bone marrow blasts following the last CTL infusion. Our in vitro and in vivo findings suggest that donor CTL have anti-leukemia properties that could potentially be exploited to improve disease-free survival post haploidentical SCT. Further studies are necessary to determine whether irradiation of CTL could preserve a GVL effect while preventing GVHD, and also determine if the in vitro culture system we describe here may itself help separate GVL and GVHD reactions.
Materials and methods

Leukemia samples
Leukemic blasts were obtained from bone marrow or peripheral blood of nine pediatric patients with newly diagnosed (n = 7) or relapsed (n = 2) ALL. Immunophenotypic analysis showed that the lymphoblasts from all nine patients expressed CD19, CD22 and HLA-DR; eight of nine expressed CD10; four also expressed CD20, and five also expressed CD34, terminal deoxynucleotidyl transferase (tdt), or both (Table 1) . The protocol for collection of marrow and blood samples for these studies was reviewed and approved by the Human Investigations Committee of Emory University School of Medicine. Informed consent for procurement of these specimens was obtained from each patient's parents and, where appropriate, consent was obtained from the patient as well. The ALL blasts were isolated from heparinized marrow and blood samples by density centrifugation over Ficoll-Hypaque-1077 (Sigma Diagnostics, St Louis, MO, USA) and two cycles of washing, centrifugation and resuspension in RPMI-1640 medium (Mediatech, Herndon, VA, USA) supplemented 
Generation of donor CTL
Mononuclear cells were isolated from peripheral blood of haploidentical parents by Ficoll-Hypaque centrifugation and were cultured in 25 cm 2 tissue culture flasks (Corning, Cambridge, MA, USA) at an initial cell concentration of 10 6 cells/ml in RPMI-1640 medium with either 10% heatinactivated AB serum or FFP, plus additives described above. Irradiated ALL blasts from their children were added to provide responder:stimulator (R:S) ratios that ranged from 3:1 to 10:1, cultures were incubated at 37°C in 5% CO 2 in humidified air. Three days later, recombinant IL-2 (Chiron, Emeryville, CA, USA) was added to cultures at a final concentration of 10 IU/ml. Cell counts were monitored every 3 to 4 days and sufficient medium was added to maintain cell concentrations at approximately 0.5 ϫ 10 6 /ml. At day 7 and weekly thereafter, cultures were restimulated by addition of irradiated ALL cells. At day 8 and continuing after, IL-2 was added to all cultures at an increased final concentration of 100 IU/ml. In some experiments, IL-7 (final concentration, 10 ng/ml) and IL-12 (final concentration, 20 ng/ml) (both Peprotech, Rocky Hill, NJ, USA) were both also added to cultures from day 3 onward to determine whether the addition of these cytokines affected the cytotoxicity of the CTL and their proliferation.
CTL cultures were also tested for expansion with OKT3 (␣CD3 antibody) (Ortho Biotech, Raritan, NJ, USA). CTL were stimulated with OKT3 after three to four stimulations with ALL blasts. The flask was coated with 10 g/ml of the OKT3 for 1 h and then washed twice with PBS to remove any excess of the antibody.
Cell-mediated cytotoxicity assay
Cytotoxicity of donor CTL against ALL blasts and the NKsensitive K562 cell line was measured in a standard 4-h 51 Cr release assay. 13 Target cells were labeled by incubation with 100 Ci 51 Cr (DuPont, Boston, MA, USA) per 10 6 cells in 1 ml of RPMI-1640 medium for 15 h at 37°C in 5% CO 2 in humidified air, centrifuged and set for 1 h wash out then washed twice, and resuspended in medium. Assays were carried out in triplicate in 96-well V-bottom microtiter plates (Corning) with 10 3 target cells per well and cultured CTL in effector:target ratios that ranged from 20:1 to 0.7:1. To provide necessary controls, spontaneous and total 51 Cr release for target cells were also determined. The microtiter plates were centrifuged for 3 min at 300 g, incubated at 37°C in 5% CO 2 in humidified air for 4 h, and then centrifuged for 10 min at 300 g. 
Concavalin A blasts
Mononuclear cells were isolated from peripheral blood of haploidentical parents by Ficoll-Hypaque centrifugation and were cultured in the presence of Concavalin A 10 g/ml (Sigma) at 10 6 cells/ml for 5 days before the assay. 
Flow cytometry
Proliferation assay
Proliferative responses of CTL to graded doses of irradiation were studied using a short-term tritiated 3 H thymidine incorporation assay. Haploidentical CTL were collected from ALL-stimulated cultures, centrifuged and resuspended in RPMI-1640 medium with additives described above and with IL-2 (final concentration, 100 IU/ml), and aliquots of cells were irradiated to a different dose of radiation with a 137 cesium source (Nordion). Assays were carried out in triplicate in 96-well round-bottom microtiter plates with 10 5 cells per well at 37°C in 5% CO 2 in humidified air for 24 h. Sixteen hours before harvesting, 1 Ci of 3 H thymidine (Dupont) was added to each well. Cells were harvested on glass fiber filters using an automated cell harvester (Tomtec, Orange, CT, USA), scintillation fluid was added, radioactivity was measured using a beta-plate counter (Wallac), and expressed as c.p.m.
QA/QC of the infused CTL
The cultured CTL were tested weekly for sterility by standard bacterial and fungal cultures. A sample was taken from each CTL product for infusion and testing performed for gram stain, bacterial and fungal cultures, and endotoxin test. CTL were tested for cytotoxicity and phenotyped on the day of infusion. Viability of the infused CTL was determined by trypan blue exclusion and in all cases was above 90%.
Results
Leukemia/parental cocultures yield CD8
+ CTL A total of 13 haploidentical parental CTL cultures were established using nine different pediatric ALL samples as stimulators. Phenotypic analysis of the leukemic blasts showed low or no expression of CD80 and CD86 in most patients (Table 1) . Cytotoxicity after the first cycle of stimulation of CTL was higher against the NK-sensitive K562 target (16%) than the ALL targets (3%), at a 20:1 E:T ratio. After the second cycle of CTL stimulation, cytotoxicity against ALL targets increased almost 13-fold to 38%, while that against K562 targets doubled to 30%. Subsequent cycles of stimulation resulted in maintenance of cytotoxicity against ALL blasts with decreasing cytotoxicity against K562 targets ( Figure 1 ). Phenotypic analysis of the 13 different CTL cultures was performed after the second or third stimulation of these cultures with irradiated ALL blasts. Cells generated were CD3 + T cells and in all cases tested expressed TCR␣␤ (data not shown). Phenotypic analysis showed that the majority of these cells were CD8 + T cells (mean 59%, range 21-96%) while a lesser percentage were CD4
+ T cells (mean 
32%, range 4-70%). Only a mean of 4% of cells had a natural killer (NK) immunophenotype (ie, CD16
+ /CD56 + ). Intracellular staining demonstrated that CTL expression of perforin was a mean of 40% which was mainly expressed by CD8
+ cells ( Figure 2 ).
Requirements for CTL cultures
To evaluate practical requirements for generation of leukemia-reactive haploidentical CTL on a clinical scale, we tested different compositions of the culture medium and different combinations of exogenous cytokines. In four representative paired experiments, there was no significant difference in cytotoxicity of CTL grown in medium that contained either 10% heat-inactivated AB serum or 10% FFP (data not shown). Also, there was no significant difference in cytotoxicity of CTL cultured with either IL-2 alone or with the combination of IL-2, IL-7 and IL-12 (data not shown). Expansion of cultured T cells was 11 to 208-fold after 3-6 weeks in culture (Table 2) . Additionally, CTL were tested for expansion with OKT3 (␣CD3 monoclonal antibody) after initial establishment with ALL blast stimulation for at least three to four stimulations. There was no significant loss of cytotoxicity after OKT3 expansion (53% compared to groups stimulated with ALL blasts 61%, n = 5). In the four cases of pediatric ALL in which leukemiareactive CTL were generated from both parents, we compared the cytotoxicity of CTL derived from both mother and father to determine whether there was any difference in CTL generation. In cytotoxicity assays against ALL blasts the mother's CTL had 33% cytotoxicity compared to 34% of father's CTL (n = 4).
Specificity of leukemia generated haploidentical CTL
To determine whether the CTL expanded in vitro had autologous cytotoxicity, CTL were tested against autologous conA lymphoblast targets. In contrast to the substantial cytotoxicity (mean, 39%) of parental CTL against haploidentical ALL blasts obtained from their children, there was only 10% cytotoxicity against autologous ConA-stimulated lymphoblasts, probably corresponding to NK cell activity at the 20:1 E:T ratio. Alloreactivity of parental CTL against ConA-stimulated lymphoblasts from the other parent (mean cytotoxicity, 55%) was comparable to that observed in response to ALL targets at that E:T ratio, likely reflecting recognition of the unshared haplotype (n = 3) ( Figure 3 ).
Effects of graded doses of gamma irradiation on the proliferative capacity of cultured CTL
A dose of 30 Gy was sufficient to reduce the maximal proliferation in response to ALL blast stimulation by 96% ( Figure 4a ) in a 24 h 3 H thymidine incorporation assay, and a dose as low as 7.5 Gy still provided 74% reduction in proliferation. Importantly, despite significantly decreased proliferation in response to alloantigens, CTL exposed to 30 Gy retained cytotoxicity against ALL targets ( Figure  4b ).
Treatment of patient with relapsed ALL post haploidentical SCT with CTL infusion
A white male was diagnosed at age 2.5 with early pre-B ALL (WBC 63 000, hyperdiploid cytogenetics, CNS negative). During week 81 of maintenance therapy he developed a BM relapse. Twenty-two months after diagnosis the patient received a haploidentical peripheral blood SCT from his father in second remission, following TBI (1400 cGy), cytoxan (120 mg/kg), and ATG (90 mg/kg). The patient and his father were fully haplotype mismatched based upon high-resolution DRB1 and serologic class I HLA typing (father: A3, A1, B60, B8, Cw10, Cw7, DRB1 14, DRB1 03; patient: A3, A68, B60, B44, Cw10, Cw7, DRB1 14, DRB1 1101). The PBSC were CD34 selected and CD2 depleted (CellPro Ceprate column) (CD34 dose 20.9 ϫ 10 6 /kg and CD3 dose 0.4 ϫ 10 6 /kg) and he received CsA/short-course MTX GVHD prophylaxis. He had 100% donor engraftment and developed GVHD clinical grade 2 which responded to steroids. He subsequently had a BM relapse 8 months later and was treated with chemotherapy, and experienced graft failure and multiple complications including congestive heart failure requiring digoxin and an acute spinal cord degeneration related to chemotherapy resulting in paraplegia. He received a second infusion of Figure 3 Alloreactivity of haploidentical CTL. CTL generated from father in cytotoxicity against ALL blasts (Ȧ), autologous father conA blasts (---) and against allogeneic mother's conA blast (---) (n = 3). The mean Ϯ one standard deviation is shown.
CD34 selected/CD2 depleted SC (CD34 36 ϫ 10 6 /kg, CD3 1.6 ϫ 10 6 /kg) from his father with 100% donor engraftment. He received no immunosuppression and did not develop any evidence of GVHD following the CD34 selected stem cell boost.
After IRB approval and informed consent, he started immunotherapy 3 months after relapse with the first dose of cultured and irradiated CTL with evidence of a new relapse with a bone marrow blast count of 22%. A total of five different CTL cultures were generated for the patient from the original donor. His father's PBMC were stimulated with irradiated relapsed ALL blasts in a ratio of 2-4:1. The CTL were grown in complete media with 10% fresh frozen plasma obtained from the blood bank and IL-2 100 U/ml. CTL cultures were tested for cytotoxicity against leukemia blasts, autologous and maternal ConA blasts and CD34
+ cells, and K562 (Table 3 and Figure 5 ). The CTL recognized the leukemia blasts along with the other parent's conA blasts, but not the father's conA blasts or CD34 infusions over a period of 2 months, along with additional in vivo IL-2 (5 ϫ 10 6 IU/m 2 /24 h continuous infusion) with the last three infusions (Figure 7) . Only the first three infusions were irradiated prior to infusion, while the sub- Figure 5 Cytotoxicity of haplo CTL from last infused batch for patient SH. Remaining CTL from batch number Ϫ08 (see Table 3 ) following infusion 9 were restimulated with ALL blasts and IL-2 and tested for cytotoxicity 1 week later against the stimulating ALL blasts, con A blasts from both parents, and CD34 selected PBPC from the donor father in a 4 h chromium release assay in the presence of an excess of cold K562 targets to minimize non-specific killing. sequent infusions were not irradiated, secondary to disease progression. Following the infusions of unirradiated CTL, we could detect small peaks in circulating perforin expressing CD8 + T cells which had been absent up till that point (Figure 8) would occur several days to a week after infusion, suggesting either initial redistribution to tissue sites before reentering the circulation, or possible limited expansion of the infused CTL. With regard to autonomous proliferation of the infused CTL, they were essentially dependent upon exogenous IL-2 in vitro, demonstrating little to no proliferation in response to irradiated ALL blasts from the patient if no exogenous IL-2 was provided ( Figure 9 ). However, if patient ALL blasts were pre-cultured with a cocktail of recombinant proteins that induced upregulation of costimulatory molecules, the haplo CTL could be induced to proliferate spontaneously, demonstrating that they were not truly anergic.
The absolute blast count went from a peak of Ͼ6000/l down to under 10/l, by the ninth infusion of CTL ( Figure  7) . A bone marrow biopsy done immediately before the ninth infusion was hypercellular with a predominance of leukemia blasts, and 11 days after the ninth infusion revealed hypocellularity with occasional leukemia blasts (Figure 10a, b) . The patient received no chemotherapy or immunosuppression during the course of the CTL infusions, strongly suggesting that the infused CTL were solely responsible for the therapeutic effect. Following the 
Figure 9
Proliferation of haplo CTL for patient SH is dependent upon IL-2 or costimulation. Paternal PB, random donor PB, or haplo CTL batch Ϫ01 and Ϫ04 (7 days following restimulation) were placed in triplicate at 5 ϫ 10 4 cells well in 96-well round-bottom plates with either media alone, IL-2 10 IU/ml, irradiated ALL.sh blasts, or irradiated ALL.sh blasts that had been precultured with IL-3, IL-7, Flt3L, and CD40L for 5 days to upregulate costimulatory molecules (responder:stimulator ratio 1:1) for 5 days, with extensive washing to remove cytokines before utilized as stimulators. Wells were pulsed for the last 16 h with 3 H thymidine; c.p.m. shown are average of triplicates with subtraction of background stimulators.
third infusion there was a transient rash, but at no other time during the course of the CTL infusions was GVHD evident. The patient unfortunately lost peripheral blood counts, and was given a boost of peripheral blood stem cells from his parental donor, which were not T cell depleted, and 9 days later developed GVHD involving skin, gut and liver along with fever and capillary leak, and despite immunosuppressive therapy he expired. He did show evidence of neutrophil recovery with an ANC of 2600 2 days before death, indicating that the CTL had no permanent effect on bone marrow function. 
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Discussion
To generate leukemia-specific or -reactive CTL, using the leukemia cells as the APC would ensure presentation of the appropriate antigens. It is generally accepted that for full activation, T cells must receive at least two signals delivered by the APC. The first is an antigen-specific signal and is delivered by antigenic peptide bound by major histocompatibility complex molecules to the T cell receptor. This signal by itself is insufficient to mediate T cell activation, cytokine production, and subsequent T cell proliferation and function. T cells require a second signal for full activation, a costimulatory signal, which involves signaling through CD80 and CD86 on the APC and CD28 on the T cell. However, ALL blasts have been shown to be deficient in expression of B7 (CD80 and CD86) costimulatory molecules 14 and to use them as an APC could result in anergy, a state of antigen-specific T cell nonresponsiveness. Others have shown upregulation of costimulatory molecules on Blineage leukemia cells by coculturing them with human CD40 ligand 15 or cross-linking the CD40 molecule on leukemic cells surface 16 resulting in induction and/or upregulation of adhesion, major histocompatibility complex, and more importantly the B7 family molecules.
In the present study, we demonstrated that unmanipulated ALL blasts are sufficiently immunostimulatory in a haploidentical mismatch to generate and expand leukemiareactive alloreactive cytolytic T cells. It is possible that the constant exposure to IL-2 bypassed the need for costimulation by the leukemia blasts. Or, it is possible that initial activation of T cells allowed for cognate T and B cell interaction resulting in CD40L signals which lead to upregulation of costimulatory molecules on the leukemia cells. 17 Additional lymphokines (IL-7, IL-12) were not necessary, indicating probable involvement of CD4 helper T cells, which are known to make a variety of lymphokines important for generation of cytotoxic T cells. Despite probable involvement of CD4 T cells, CD8
+ T cells were preferentially expanded (Figure 2) . It is also possible that the ALL blasts themselves secrete important lymphokines, for example IL-12, which is important for generation of alloreactive CTL 18 and was first described as a product of malignant B lineage cells. 19 An important issue in this study is to demonstrate the specificity of the CTL generated using this methodology. Our results show that leukemia-reactive CTL lysed ALL blasts in all patients more efficiently compared to the NKsensitive K562 cell line, after priming CTL with irradiated leukemia blasts (Figure 1 ). This implies that the cytotoxicity is mediated primarily by MHC restricted cytotoxic T cells and not non-MHC restricted LAK-type cells. This was supported by blocking studies on the CTL generated and infused into the one patient we report. Importantly, these allogeneic CTL do not recognize and lyse autologous conA lymphoblast targets (Figure 3) , or CD34 selected autologous stem cells ( Figure 5 ). With regard to leukemia specificity, parental CTL recognized and lysed the alternate parental targets as well as the stimulating leukemia blasts, demonstrating the allo-antigen specificity of the T cell population (Figures 3 and 5) . In the clinical case, we demonstrated that blocking CD8 + T cells eradicated most of the cytotoxicity, while CD4 blocking had little effect ( Figure  6 ), suggesting that the cells responsible for the anti-leukemic effect were likely to be CD8 + alloreactive CTL. Furthermore, the cultured CD8 + T cells had a high expression of perforin (Figure 2) , indicating likely involvement of this pathway in the anti-leukemia activity, as has been described in murine GVL models. 20 Because these haplo CTL were shown in vitro to be alloreactive and not leukemia specific, as a strategy to prevent GVHD without loss of the beneficial GVL effect, the CTL were irradiated without altering short-term anti-leukemia cytotoxicity (Figure 4b) . 21 The dose of 3000 cGy led to almost complete inhibition of proliferation in response to antigen + IL-2, suggesting that there would be little chance for further proliferation of the CTL if infused into patients. The initial intent in treating the reported patient was to infuse increasing doses of irradiated haplo CTL on a weekly schedule, with a high expectation of at least transient GVHD. However, only the initial three infusions were irradiated, and due to rapid disease progression the subsequent six infusions were not irradiated (Table 3 and Figure 7) . The surprising finding was that GVHD was not immediately apparent following even the unirradiated CTL. The patient did eventually die of overwhelming grade IV GVHD; however, this developed at the time he was engrafting following infusion of unmanipulated haploidentical PBPC from the original donor. While it is impossible to rule out a contribution of the infused cultured CTL to the eventual development of GVHD, it seems unlikely that the earliest infusions would have contributed significantly. For example, the seventh infusion consisted of 10 ϫ 10 7 CTL/kg body weight, and was given on day 34 from initiation of CTL therapy, and GVHD did not become evident until 38 days later, making it unlikely that the infused CTL from that timepoint would have contributed to GVHD. This would strongly support a conclusion that the in vitro culture process somehow limits the GVHD potential of alloreactive T cells.
We and others have shown in mouse models that preculturing donor splenocytes with either normal or leukemic host-type hematopoietic cells to generate cytotoxic effector cells, can diminish their in vivo GVHD potential in mismatched allogeneic BMT. Fowler and colleagues 22 showed in a mouse haploidentical transplant model that cultured alloreactive Tc1 CTL had equivalent GVL potential compared to naïve CD8 + allogeneic T cells. However, the Tc1 CTL resulted in limited GVHD while the same dose of naïve CD8
+ T cells resulted in severe and progressive GVHD. Cultured Tc2-type allogeneic T cells had even more attenuated GVHD potential than did Tc1 cells. Additionally, they have generated alloreactive Th1 and Th2 type CD4
+ T cell populations to assess their potential to cause GVHD. We have shown in a complete mismatch transplant model that CTL cultured in vitro with IL-2 against an AML cell line had approximately a 20-fold higher GVL potential compared to whole splenocytes when infused on day 30 post transplant. However, the same populations infused on day 0 demonstrated that the splenocytes resulted in rapid and lethal GVHD while no clinical GVHD developed from the cultured CTL. 24 Martin and colleagues 25 studied the effect of preactivation by MLC on CD8 + T cells to mediate graft promotion vs GVHD in a T cell-depleted haploidentical murine transplant setting. A dose of activated CD8 + T cells five-fold higher than naïve CD8
+ T cells was required to mediate engraftment in this graft rejection model. Furthermore, recipients of 10 6 activated CD8 + T cells all engrafted without GVHD, while recipients of 10 6 naïve CD8 + T cells also engrafted but with GVHD. They further characterized four CTL clones obtained from the MLC activated CD8
+ bulk population. Three of four clones had no toxicity when up to 20 ϫ 10 6 cells were infused into irradiated hosts that expressed the stimulating alloantigen, even when exogenous IL-2 was administered to recipients for 7 days. One non-toxic clone was able to prevent graft rejection when large numbers were infused with exogenous IL-2, and did not cause clinical or histologic GVHD. One of four clones resulted in rapid lethal toxicity. Thus, in at least three separate murine systems there has been documentation that culturing allogeneic CTL in vitro can result in diminished GVHD potential with retention of therapeutic GVL or graft promotion properties. The fact that one group of the cloned CTL caused rapid lethal toxicity (on autopsy demonstrated to be pulmonary vascular leak), and that cultured Th1-type CD4
+ cells could cause rapid GVHD of course raises the concern that alloreactive cultured T cells could cause rapid and overwhelming toxicity. However, the doses of cells infused in those cases were 10 7 /mouse for the CTL and 2.5 ϫ 10 7 /mouse for the Th1 cells, or equivalent to roughly 2.5 ϫ 10 8 to 10 9 cells/kg body weight if translated into humans, a dose one to two logs higher than we infused.
The mechanism(s) by which in vitro culture could attenuate GVHD remains uncertain. In addition to the above mention of Th2 downregulation of Th1 GVHD, a second possible explanation could be that in vitro culturing in the presence of IL-2 leads to generation of only effector type cells without memory function. 26 The effector CTL generated by our method may therefore be short-lived and not fully capable of establishing GVHD. Several pieces of data would support that hypothesis. First, we have recently demonstrated on cryopreserved CTL from the treated patient that the T cells undergo activation-induced cell death in response to OKT3 with or without IL-2 (41% annexin pos/7AAD neg with OKT3 10 ng/ml, normal PBMC Ͻ1% annexin pos or 7AAD pos). Secondly, again using cryopreserved CTL from the patient as well as recently established cultures we have seen that both naïve and central memory T cells (based upon CD45RA and CCR7 expression), 26 disappear from culture over 4-6 weeks time. The representative cryopreserved CTL from the treated patient were virtually all effector memory phenotype, with no CD45RA and little or no CCR7, and very low (6%) CD62L. This phenotype has been described as having poor ability to generate IL-2, but instead to make high amounts of IFN-␥ as well as perforin in the case of CD8 + T cells, and have shortened telomere length. 26 In contrast, we showed no evidence that the cultured CTL were anergized, since they proliferated without exogenous cytokines in response to leukemia blasts that had upregulated costimulatory and adhesion molecules ( Figure 9 ). This should not be surprising given that exogenous cytokines that stimulate through the ␥c chain prevent T cell anergy. 27 A third possibility is that the process of in vitro culture preferentially expands T cells with relative hematopoietic restricted alloantigen specificity. Others have shown that
Bone Marrow Transplantation use of endothelial cells either alone or in combination with EBV-LCL in stimulation of allogeneic CD8 + T cells lead to generation of endothelial-specific CTL lines after only 2 weeks in culture, which was different to the CTL lines generated with EBV-LCL alone. 28 This would support the idea that the cell type in the initial culture of alloreactive CTL can alter the specificity of the T cells eventually obtained. We think it is possible that the use of the leukemia blasts, which are non-professional antigen-presenting cells, as the primary stimulator could skew the CTL response toward hematopoietic restricted alloantigens; our future studies hope to address this issue.
A fourth possibility relates to the in vivo homing potential of in vitro cultured T cells. It is well described that the T cells found in specific tissue sites such as lymph nodes, skin, or gut mucosa have a specific pattern of adhesion molecules and chemokine receptors that are thought to direct their homing from the circulation (reviewed in Ref. 29) . This is in part the basis of separation of subsets of memory T cells based upon the chemokine receptor CCR7 and the adhesion molecule CD62L (L-selectin). As mentioned above, the infused CTL were found to have no expression of CCR7 and only 6% expression of CD62L, making it unlikely that they would home effectively to the lymph nodes. Altered homing of cultured murine T cells that is related to downregulation of CD62L was described quite some time ago. 30 It has been recently described that blocking L-selectin along with ␣4-integrin ameliorates GVHD in a murine model. 31 We have preliminarily looked at expression of CCR4 and CLA, which are involved in skin homing, and CCR9, which is involved in homing to the gut mucosa and have found that these are down-regulated by in vitro culture with leukemia blasts. These preliminary results would provide a hypothetical mechanism whereby fully alloreactive CTL could be infused into a host and not cause tissue-specific GVHD reactions.
The patient received no chemotherapy or immunosuppression during the course of CTL infusions. We observed an anti-leukemia response without GVHD despite demonstration that the infused CTL were fully alloreactive. Furthermore, we observed an anti-leukemia response in both the peripheral blood and the bone marrow, suggesting that the infused CTL were capable of trafficking to the bone marrow space. The treated patient unfortunately lost peripheral blood counts, and required a boost of peripheral blood stem cells from his paternal donor, which were not T cell depleted, and 9 days later developed GVHD involving skin, gut, and liver along with fever and capillary leak, and despite immunosuppressive therapy he expired. He did show evidence of peripheral blood count recovery (ANC 2600) before expiring, indicating that the CTL had no permanent effect on bone marrow function. The most likely explanation for the loss of normal blood counts was progression of leukemia, since the BM was almost completely infiltrated with ALL blasts on day 53 of the CTL infusion (Figure 10a ).
In conclusion, our data demonstrate that human ALL blasts are sufficient to present alloantigen to haploidentical T cells which in the presence of exogenous IL-2 results in expansion of CTL capable of GVL reactions in vitro and in vivo. These in vitro generated alloreactive CTL may have an altered GVHD potential allowing infusion without any further manipulation to treat relapsed leukemia post haploidentical transplant. Alternatively, pretreatment with radiation prevents further proliferation while preserving their in vitro anti-leukemia effects, potentially allowing for infusion into patients even if GVHD potential still exists. Our data demonstrate that haploidentical leukemia-reactive CTL could potentially be used as a strategy to treat relapse or minimal residual leukemia following haplotype mismatched HSCT. A phase I dose escalation study with preemptive addback of unirradiated haploidentical CTL for refractory ALL is planned, however, many unresolved issues remain in order to fully exploit the potential of cultured T cells for therapy.
